BMI significantly influenced the efficacy of anti-tumour strategies, but there are fewer studies on the relationship between BMI and the therapeutic effects of CDK4/6 inhibitors, and existing research generally suggests that BMI was not associated with the prognosis of CDK4/6 inhibitor therapy. This evidence concerns the gene CDK4 and neoplasm.